Citations

Clear

1055 citation(s) found for "Small, J C".

Comparative efficacy of immune checkpoint inhibitor–anti-VEGF inhibitor combinations in non–small cell lung carcinoma: A network meta-analysis of randomized trials.
Haseeb, Rafay, ARSHAD, H, Raza, Muhammad Zain, Gill, Omar Abdullah , Maqsood, Musab , Habib, Huzefa, Chaudhary, Hamza, Komel, Aqsa, Raza, Muhammad Zain , Talha, Muhammad

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e20629 Get It

e20629 Background: Concomitant inhibition of the vascular endothelial growth factor (VEGF) pathway together with PD-1 or PD-L1 immune checkpoint blockade has demonstrated synergistic activity in non-small cell lung cancer (NSCLC). However, comparative evidence across individual immune checkpoint inhibitor (ICI) and anti-VEGF combinations remains limited. This network meta-analysis (NMA) aimed to evaluate and compare the efficacy of available ICI plus anti-VEGF combination strategies in NSCLC. Methods: A systematic search of three electronic databases and two clinical trial registries was conducted to identify randomized controlled trials evaluating combinations of ICIs with anti-VEGF agents. A frequentist NMA framework was applied using the netmeta package in R. Hazard ratios (HRs) were used for overall survival (OS) and progression-free survival (PFS), while odds ratios (ORs) were used for objective response rate (ORR). Treatment ranking was performed using P scores. Results: A total of 24 randomized controlled trials were included in the network. For survival outcomes, the combination of nivolumab plus bevacizumab demonstrated significantly improved OS (HR = 0.66, 95% CI 0.50–0.88) and PFS (HR = 0.46, 95% CI 0.27–0.81) compared with standard chemotherapy. In addition, atezolizumab plus bevacizumab was associated with a significant OS benefit over chemotherapy (HR = 0.79, 95% CI 0.65–0.95). Indirect comparisons showed that nivolumab plus bevacizumab significantly improved PFS compared with pembrolizumab monotherapy, as well as pembrolizumab combined with lenvatinib or chemotherapy. Furthermore, nivolumab combined with sitravatinib demonstrated significantly superior OS and PFS compared with ramucirumab and chemotherapy. For ORR assessed using RECIST 1.1, nivolumab-based combinations could not be incorporated into the network due to insufficient data, and no other combination demonstrated a statistically significant advantage over chemotherapy. However, indirect comparisons showed that pembrolizumab plus lenvatinib was superior to lenvatinib monotherapy (OR = 4.76, 95% CI 1.04–25.0). P-score rankings identified nivolumab plus bevacizumab as the top-ranked regimen for survival outcomes, followed by atezolizumab plus bevacizumab. For ORR, pembrolizumab plus lenvatinib ranked highest, followed by atezolizumab plus bevacizumab. Conclusions: Nivolumab-based ICI and anti-VEGF combinations, particularly with bevacizumab and sitravatinib, demonstrate the most favorable survival outcomes in NSCLC. Evidence for ORR remains limited, and further randomized comparisons are required to better define the relative efficacy of these combinations.
Effect of immune checkpoint inhibitor infusion timing on overall survival in non–small cell lung cancer: A real-world retrospective study.
Ganatra, Nency, Abdelhakeem, Ahmed, Jain, Pragya , Doshi, Jinish , Patel, Shivam Chetankumar, Arya, Yajur , Adeoye, Oluwatayo , ELANTABLY, DINA, Naqvi, Tahir, Lou, Yanyan, Ganatra, Nency, Elantably, Dina, Lou, Yanyan

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e20595 Get It

e20595 Background: Circadian regulation of immune function has been proposed as a modifier of immune checkpoint inhibitor (ICI) efficacy, with retrospective studies suggesting improved outcomes with earlier infusion timing. Whether these findings translate to routine oncology practice, where ICIs are administered across multiple lines, frequently combined with chemotherapy, and subject to treatment interruptions, remains uncertain. We evaluated the association between ICI infusion timing and overall survival (OS) in a real-world cohort of patients with non-small cell lung cancer (NSCLC). Methods: A retrospective cohort study included adults with NSCLC who received at least one line of ICI therapy at a community oncology center between January 2018 and December 2024. Infusion timing was defined at the patient level as morning-only ( < 1300 hours), evening-only (≥1300 hours), or mixed timing, reflecting receipt of infusions exclusively in different time-of-day categories across treatment lines. OS was measured from diagnosis to death or last follow-up. Kaplan-Meier and Cox proportional hazards models were used. Multivariable analyses adjusted for stage, ECOG performance status, body mass index, and premature ICI discontinuation. Line of therapy was excluded due to collinearity with mixed-timing classification and risk of immortal time bias. Results: A total of 127 patients were included (morning-only n = 77; mixed timing n = 36; evening-only n = 14). Staging data were available for 99.2%, and 94 deaths occurred. Median OS was 495 days for morning-only, 850 days for mixed timing, and 388 days for evening-only patients. Kaplan-Meier analysis showed no statistically significant OS differences across groups. In sensitivity analysis excluding patients with mixed infusion timing, morning-only and evening-only groups demonstrated overlapping survival curves, with no evidence of a time-of-day–specific survival advantage. In univariate analysis, mixed timing was associated with a borderline reduction in mortality compared with morning-only infusions (HR 0.63, 95% CI 0.39-1.00), while evening-only timing was not (HR 1.63, 95% CI 0.85-3.16). In multivariate analysis restricted to stage III-IV disease, infusion timing was not independently associated with OS. ECOG performance status, premature ICI discontinuation and advanced staging were the strongest predictors of mortality. Conclusions: In this real-world NSCLC cohort, ICI infusion timing was not independently associated with overall survival after adjustment for patient fitness and treatment continuity. These findings suggest that in pragmatic settings, clinical factors may outweigh subtle chronotherapy effects reported in more selected populations.
Efficacy and patient-reported outcome of trophoblast cell surface antigen-2 antibody-drug conjugate in advanced non–small cell lung cancer: An individual patient data survival analysis and meta-analysis.
Gandicheruvu, Haritha, Walia, Kamalpreet Singh Singh, Batra, Nitya, Keen, Mahnoor Asghar, Kakarala, Chandra, Ammakola, Yagnapriya, Deshmukh, Sameer , Kumar, K Senthil , Sukaina, Mahnoor , Walia, Kamalpreet Singh, Kakarala, Chandra , Ammakola, Yagnapriya, Khosla, Atulya Aman , Jatwani, Karan , Singh, Rohit

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e20511 Get It

e20511 Background: Trop-2 ADCs have emerged as a novel therapeutic approach in NSCLC that is refractory to chemotherapy and immune checkpoint inhibitors. Comparative interpretation of the efficacy of multiple Trop-2 ADCs, including Sacituzumab tirumotecan (Sac-TMT), Datopotamab deruxtecan (Dato-DXd), and Sacituzumab govitecan (SG), is limited. We therefore conducted a systematic review, IPD survival analysis, and meta-analysis to evaluate the efficacy and PROs of Trop-2 ADCs compared with chemotherapy in NSCLC. Methods: A systematic search was conducted from inception to October 31, 2025, across PubMed, Scopus, Cochrane, and CT.gov. Clinical trials evaluating Overall Survival (OS) and Progression-free survival (PFS) in patients treated with Trop-2 ADC alone or compared with Chemotherapy were included. IPD were extracted from the Kaplan-Meier curves of clinical trials for reconstruction using the KMfromIPD website by MD Anderson, which stratified the data by treatment group. Outcomes included OS, PFS, and time to deterioration (TTD). The cumulative data were analyzed using R 4.5.1 and RStudio. RevMan version 5.4.1 was used for the meta-analysis of subgroups. Heterogeneity was assessed using the I 2 statistic. Results: Of 513 articles, 7 phase 1/2 single-arm and 4 randomized control trials were included, comprising 2,619 patients.Trop-2 ADCs were associated with improved OS (Median 15.6 vs 12.5 months; HR 0.78, 95% CI 0.69-0.88; p < 0.0001) and PFS (Median 5.5 vs 4.1 months; HR 0.66, 95% CI 0.59-0.74; p < 0.0001). Sac-TMT demonstrated the greatest OS benefit (OS 23.3 months; HR 0.40). Further drug classes are depicted in Table 1. PROs assessment showed TROP-2 ADCs were associated with longer time to deterioration in global quality of life and dyspnea-free survival compared to chemotherapy (HR 0.8 and 0.69), (p = 0.04 and p < 0.0001, respectively). Exploratory subgroup analysis showed improved OS among patients with actionable gene alteration (AGA) treated with Trop-2 ADCs (HR 0.58, p < 0.00001). However, no significant difference was observed in either treatment arm among patients without AGA (HR 0.89, p = 0.15). Conclusions: Trop-2 ADCs were associated with improved survival and PROs compared with chemotherapy in NSCLC, with variability across agents. Sac-TMT has shown higher OS and PFS. Dato Dxd had a favorable PFS; however, the OS was not superior to chemo. Furthermore, SG showed no favorable clinical outcomes compared with the chemo group. These findings support the continued development of Trop-2-directed therapies and highlight the need for prospective comparative trials and biomarker-driven patient selection. Drug N mOS (months) HR p- value mPFS (months) HR p- value Sac-TMT 386 23.32 0.4 <0.000001 7.5 0.5 <0.000001 Dato-DXd 486 13.2 0.95 0.55 5.02 0.71 <0.000001 SG 347 12.61 1.02 0.82 4.18 0.87 0.05
Baseline brain metastases as a prognostic factor in extensive-stage small cell lung cancer treated with first-line chemo-immunotherapy: A systematic review and meta-analysis.
Tareen, Haseeb, Dad, Allah , Arham, Muhammad , Tahir, Haris Bin , Kumar, Priya, Jamil, Maria , Ahmed, Hafsa, Khalid, Misha , Marsool, Mohammed Dheyaa, Sami, Muhammad Mohsin , Daim, Safi Ur Rehman , Habib, Huzefa, Iftikhar, Ahmad , Tareen, Haseeb Khan , Marsool, Mohammed Dheyaa Marsool , Ashraf, Muhammad Fawad , Ahmad, Rana Uzair , Siddiqi, Ahsun Rizwan

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e20139 Get It

e20139 Background: Extensive-stage small cell lung cancer (ES-SCLC) frequently presents with brain metastases, affecting approximately 20% of the patients at diagnosis. The prognostic impact of baseline brain metastases on survival outcomes in patients treated with contemporary chemo-immunotherapy remains unclear, creating uncertainty in first-line treatment selection for this high-risk population. We conducted a systematic review and meta-analysis to evaluate the impact of baseline brain metastases on treatment outcomes in ES-SCLC. Methods: This PRISMA-compliant systematic review and meta-analysis was prospectively registered in PROSPERO. PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were systematically searched from database inception through January 2026 to identify randomized controlled trials evaluating PD-1/PD-L1-based chemo-immunotherapy versus platinum-etoposide chemotherapy in adults with ES-SCLC. Two reviewers independently screened studies and extracted data, with discrepancies resolved by consensus. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were pooled separately for patients with baseline brain metastases (BM+) and without brain metastases (BM−) using random-effects models with Hartung–Knapp adjustment. Analyses were performed using R. Prespecified subgroup analyses were conducted based on follow-up duration and immunotherapy regimen. Results: Twelve randomized controlled trials were included. Among patients with baseline brain metastases (BM+), pooled OS from seven studies did not show a significant survival benefit (HR 0.84, 95% CI 0.66–1.08, I² = 0.0%, P = 0.145), nor did pooled PFS from five studies (HR 1.03, 95% CI 0.60–1.79, I² = 0.0%). Subgroup analyses revealed no significant heterogeneity. In contrast, among patients without baseline brain metastases (BM−), pooled OS from nine studies demonstrated a significant survival benefit (HR 0.72, 95% CI 0.69–0.76, I² = 0.0%, P < 0.001), with corresponding improvement in PFS (HR 0.70, 95% CI 0.60–0.82, I² = 0.0%). These findings indicate a differential treatment effect according to baseline brain metastasis status. Conclusions: First-line chemo-immunotherapy does not apprear to confer a significant survival benefit in ES-SCLC patients with baseline brain metastases, reflecting a differential treatment effect by brain metastasis status. These findings suggest that baseline brain metastases should be considered in treatment selection and future clinical trial design and highlight the need for optimized systemic strategies for this high-risk population.
Serum magnesium level and survival outcomes in extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy: A retrospective cohort study.
Resnick, Adam, Dhanorker, Atul S., Leventakos, Konstantinos, Liu, Bolun , Resnick, Adam

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e20030 Get It

e20030 Background: Recent studies suggested associations between higher serum Magnesium (Mg) level and better survival outcome in patients receiving immunotherapy, especially in small cell lung cancer (SCLC). However, the prognostic significance of Mg in extensive-stage (ES) SCLC treated with first-line chemoimmunotherapy remains unclear. We evaluated the association between baseline serum Mg and survival outcomes in ES-SCLC receiving platinum–etoposide plus PD-(L)1 blockade. Methods: We conducted a retrospective cohort study of adults with ES-SCLC treated with first-line platinum–etoposide plus atezolizumab or durvalumab at Mayo Clinic via Mayo Clinic Platform in 2018–2025. Baseline average serum Mg level was defined as the mean of all Mg labs from day −30 to day 0 relative to chemoimmunotherapy initiation and categorized as low ( < 1.7 mg/dL), normal (1.7-2.0 mg/dL), or high ( > 2.0 mg/dL) using clinical cutoff. Low and normal groups were combined a priori due to small low-Mg counts. The primary endpoint was overall survival (OS), estimated by KM and compared by log-rank test. OS was measured from chemoimmunotherapy initiation to death and censored at last follow-up. Multivariable Cox proportional hazards models adjusted for age, gender, ECOG, liver/brain metastases status, and smoking status. Results: The cohort included 214 patients, 124 (58%) were female; median age was 68 years; 49% had liver metastases and 30% had brain metastases. Median OS was 10.4 months (95% CI 7.6-15.9) among 99 patients with high serum Mg level, compared with 7.5 months (95% CI 6.7-10.7) in 115 patients with low or normal serum Mg level (Log-rank p = 0.126). High Mg was associated with a trend toward longer OS in unadjusted analyses (Hazard ratio [HR] 0.80, 95% CI 0.59-1.07, p = 0.129); however, the association was not statistically significant after multivariable adjustment (aHR 0.81, 95% CI 0.60-1.10, p = 0.180). Conclusions: Among patients with ES-SCLC treated with first-line platinum–etoposide plus PD-(L)1 blockade, higher baseline serum Mg was associated with numerically longer OS but was not independently associated with survival after multivariable adjustment. These findings suggest baseline serum Mg level may be associated with prognosis and warrant validation in larger cohorts. Baseline characteristics by baseline serum magnesium category in ES-SCLC treated with first-line chemoimmunotherapy. Variable Overall (N=214) High Mg >2.0 (n=99) Low/Normal Mg ≤2.0 (n=115) p value* Age, median (IQR) 68 (62, 74) 68 (61, 74) 69 (62, 75) 0.201 Female, n (%) 124 (58%) 57 (58%) 67 (58%) >0.999 ECOG ≥2, n (%) 58 (27.1%) 28 (28%) 30 (26%) 0.719 Liver metastases, n (%) 105 (49%) 49 (49%) 56 (49%) 0.648 Brain metastases, n (%) 65 (30%) 33 (33%) 32 (28%) 0.469 Ever smoker, n (%) 197 (92.1%) 90 (90.9%) 107 (93.0%) 0.974 *p values: Wilcoxon (age); χ²/Fisher (categorical).
Real-world outcomes of FOLFOX with or without bevacizumab in small bowel and ampullary adenocarcinoma: A propensity-matched analysis.
Adeoye, Oluwatayo , Arya, Yajur , Syal, Arshi , Mahadevia, Himil, Palma, Angimar Uriepero, Jones, Colton, Abdelhakeem, Ahmed, O'Donnell, C., Mahadevia, Himil

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16488 Get It

e16488 Background: Small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (ampullary AC) are rare gastrointestinal (GI) malignancies. Treatment strategies are largely extrapolated from colorectal cancer, where oxaliplatin-based regimens are the most common first-line therapy in advanced disease. Although bevacizumab is considered safe in metastatic SBA, its efficacy remains unproven, and evidence is limited to small retrospective studies. We assessed the association of adding bevacizumab to FOLFOX with survival and toxicity in a large real-world cohort. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network (January 2000-December 2025), including data from 105 healthcare organizations. Adults (≥18 years) with SBA or ampullary AC treated with FOLFOX with or without bevacizumab were identified. Cohorts were propensity score-matched on age, sex, race, comorbidities, and metastatic sites. Outcomes included overall mortality, GI perforation, bleeding, venous thromboembolism (VTE), hospital admission, and emergency department (ED) visits. Kaplan-Meier and Cox proportional hazards models were used for time-to-event analyses. Results: After matching, 818 patients were included in each cohort. In the FOLFOX + bevacizumab cohort, mean age was 66.1 ± 12.0 years and 53.8% were male; 63.7% were White, 13.8% Black, 5.6% Asian, 12.0% Unknown/Other, and 4.4% Hispanic/Latino. Over a median follow-up of 13 months, FOLFOX + bevacizumab was associated with higher overall mortality compared with FOLFOX alone (55.3% vs 45.2%; HR 1.24 [95% CI 1.1-1.4]; p = 0.002) and shorter median OS (15.1 vs 19.5 months). Rates of GI perforation (15.5% vs 16.7%; HR 0.90 [95% CI 0.71-1.15]; p = 0.39), GI bleeding (13.1% vs 13.6%; HR 0.96 [95% CI 0.73-1.25]; p = 0.74), and VTE (19.1% vs 21.4%; HR 0.88 [95% CI 0.71-1.09]; p = 0.23) were similar between groups. Hospital admissions were higher in the FOLFOX + bevacizumab cohort (2.8% vs 1.3%; HR 2.1 [95% CI 1.0-4.3]; p = 0.04). Findings were consistent at 5-year follow-up. Conclusions: In this real-world cohort, the addition of bevacizumab to FOLFOX was not associated with improved survival and was associated with higher healthcare utilization. Prospective, disease-specific studies are needed to define its role in this population. Outcomes at median 13-month follow-up after propensity matching (FOLFOX + bevacizumab vs FOLFOX). Outcome % vs % HR p Overall mortality 55.3 vs 45.2 1.24 0.002 Hospital admission 2.8 vs 1.3 2.1 0.04 ED visit 45.2 vs 42.4 1.02 0.75 GI perforation 15.5 vs 16.7 0.90 0.39 GI bleeding 13.1 vs 13.6 0.96 0.74 VTE 19.1 vs 21.4 0.88 0.23
Epidemiology, survival disparities, and future incidence projections of small intestine neuroendocrine carcinoma in the United States: A population-based SEER analysis.
Shah, P.S., Mal, Madho, TUMMALA, NAYANIKA, Nimmagadda, Rithish , Keswani, Shiwani, Jawed, Inshal, Gundakaram, Samhitha, Shah, Vedant , Rawal, Shalin, Nisha, Fnu, Shah, Parth Jay, Maroules, Michael, Nookala, Vinod, Shah, Nandan, Shah, Parjanya, Jawed, Inshal , Gundakaram, Samhitha , Kumar, Love

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16322 Get It

e16322 Background: Small intestine neuroendocrine carcinoma (NEC) is a rare, aggressive malignancy comprising less than 0.1% of gastrointestinal cancers. Population-level data remain limited, restricting understanding of long-term survival patterns, demographic disparities, and evolving disease burden. We evaluated survival outcomes, demographic predictors, and incidence trends of small intestine NEC in the United States. Methods: We conducted a retrospective population-based cohort study using SEER Research Data (17 registries, November 2024 submission). Patients diagnosed with malignant small intestine NEC (ICD-O-3 morphology code 9.3.3.1.2) between 2000 and 2022 were identified using SEER*Stat (v9.0.4.2). Variables including age group, sex, race, year of diagnosis, survival time, and vital status were analyzed in R (v4.5.1). Overall survival (OS) was estimated using Kaplan–Meier methods and compared using log-rank testing. Cox proportional hazards models identified independent predictors of OS. Annual case counts were modeled using time-series forecasting to project future incidence. Results: A total of 506 patients were included. Estimated OS was 94.4% (95% CI 92.4–96.4) at 1 year, 88.1% (85.3–91.0) at 3 years, and 82.4% (79.0–85.9) at 5 years, with a subset demonstrating survival beyond 15 years. Increasing age was associated with worse survival (log-rank p = 0.058). Significant racial differences in OS were observed (log-rank p < 0.0001). In multivariable analysis, race remained independently associated with OS. Incidence forecasting projected a modest increase in annual case burden over the next decade. Conclusions: Small intestine NEC demonstrates heterogeneous survival outcomes, significant demographic disparities, and projected growth in disease burden. These findings highlight the need for improved risk stratification, equitable access to care, and integration of molecular and treatment-level data to optimize management of this rare malignancy
Early lipid-lowering therapy initiation after lorlatinib and clinical outcomes in non–small cell lung cancer: A propensity-matched real-world analysis.
Gopu, Sooraj Srirangadhamu , Agrawal, Siddharth Pravin, Chandani, Kanishka Uttam, Thukral, Jatin, Lussier, Amanda, Jajja, Salman, Tajiknia, Vida , Patel, Anjali, Abdalla, Ahmad, Agrawal, Siddharth Pravin, Thukral, Jatin, Nadeem, Ahmed

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8597-8597

10.1200/jco.2026.44.16_suppl.8597 Get It

8597 Background: Lorlatinib improves outcomes in NSCLC but commonly causes marked hyperlipidemia, prompting initiation of lipid-lowering therapy (LLT). Beyond lipid control, LLT may be associated with vascular events; however, its association with thromboembolism, healthcare utilization, and mortality among lorlatinib-treated patients has not been characterized in real-world cohorts. Methods: Using TriNetX, we identified adults with NSCLC who received lorlatinib (index = first lorlatinib record). Patients were grouped by early LLT initiation within 30 days of index versus no LLT within 30 days. LLT included statins, ezetimibe, PCSK9 inhibitors, or fibrates. Cohorts were balanced 1:1 using propensity score matching on demographics and baseline comorbidities. Outcomes were assessed through 365 days; patients with prior outcome documentation were excluded. Results: After matching, 387 patients per cohort were analyzed. Early LLT was associated with lower all-cause mortality at 365 days (16.1% vs 26.4%; risk ratio [RR] 0.61, 95% CI 0.46-0.81; p=0.0004) and improved time to death (hazard ratio 0.60, 95% CI 0.44-0.82). Early LLT was also associated with lower venous thromboembolism (6.2% vs 12.1%; RR 0.51, 95% CI 0.30-0.86; p=0.0093) and fewer inpatient hospitalizations (14.6% vs 23.6%; RR 0.62, 95% CI 0.40-0.97; p=0.0320). Emergency department visits were numerically lower (8.3% vs 13.9%; RR 0.59, 95% CI 0.35-1.00; p=0.0467). No significant differences were observed for acute kidney injury or major adverse cardiovascular events. Conclusions: In a real-world propensity-matched cohort of lorlatinib-treated NSCLC patients, LLT initiated within 30 days was associated with lower 1-year mortality, venous thromboembolism, and hospitalization. Given the frequency of lorlatinib-associated dyslipidemia, these findings support early lipid monitoring and timely LLT initiation in practice. Prospective studies are warranted to confirm these associations. 365-day outcomes after matching. Outcome Early LLT (n=387) No early LLT (n=387) RR (95% CI) HR (95% CI) p All-cause mortality 16.1% 26.4% 0.608 (0.458-0.806) 0.597 (0.435-0.818) 0.0004; log-rank 0.001 Venous thromboembolism 6.2% 12.1% 0.509 (0.302-0.857) — 0.0093 Inpatient hospitalization 14.6% 23.6% 0.619 (0.396-0.967) — 0.0320 ED visit 8.3% 13.9% 0.593 (0.352-1.001) — 0.0467 Acute kidney injury 5.4% 7.1% 0.769 (0.429-1.378) — 0.3758 MACE 4.6% 4.6% 1.006 (0.511-1.979) — 0.9868
AI-derived CD8⁺ cytotoxic T-cell immune signatures from baseline H&E images to predict immunotherapy benefit over chemotherapy in non–small cell lung cancer: Blinded validation in CheckMate-227 (CM227).
Barrera, Cristian , Safta, Wiem, Mutha, Pushkar, Grootendorst, Diederik J., Mustatea, Oana, Eddy, Nathanial, Pathak, Tilak, Gregorio, Miguel Lopez de Rodas, Schalper, Kurt A , Ramalingam, Suresh S., Velcheti, Vamsidhar, Madabhushi, Anant, Mutha, Pushkar , Khorrami, Mohammadhadi , Grootendorst, Diederik J., Eddy, Nathanial R., Rodas, Miguel López de , Ramalingam, Suresh S. , Madabhushi, Anant

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8534-8534

10.1200/jco.2026.44.16_suppl.8534 Get It

8534 Background: Immunotherapy (IO) has transformed treatment for non–small cell lung cancer (NSCLC), but not all patients (pts) benefit, underscoring the need for predictive biomarkers to guide IO versus chemotherapy (Ch). CheckMate 227 (CM227; NCT02477826) showed a survival benefit of first-line nivolumab plus ipilimumab (nivo+ipi) over Ch in stage IV NSCLC. CD8⁺ T cells are key mediators of antitumor immunity and are associated with IO benefit. We developed an artificial intelligence (AI)–based pipeline (VIGOR-CD8) that predicts spatial CD8⁺ immune signatures from routine baseline H&E whole-slide images using histopathology foundation model embeddings (H-Optimus-0) and virtual gene expression modeling (HE2Gene), and evaluated its ability to identify pts who do and do not derive IO benefit over Ch in CM227. Methods: 1,598 pts with advanced NSCLC were analyzed, including multi-institutional retrospective cohorts (n = 487; 65 for patch-level CD8⁺ prediction and overall survival (OS), 422 for patient-level OS) and a blinded CM227 validation subset (n = 1,111). For orthogonal validation, 86,470 H&E patches were co-registered with quantitative CD8⁺ immunofluorescence. H-Optimus-0 and HE2Gene immune-related embeddings were used to train a random forest classifier to predict patch-level CD8⁺ probability. Patch-level probabilities were aggregated into a patient-level CD8⁺ signature and dichotomized into biomarker-positive (B⁺) and biomarker-negative (B⁻) groups by the training-set median. Cox models assessed the impact of VIGOR-CD8 on OS. In CM227, prognostic and predictive utility were evaluated using treatment-specific analyses; investigators were blinded to outcomes, and models were trained on independent, non-overlapping cohorts. Results: VIGOR-CD8 was associated with longer OS in the testing cohort (n = 422; HR 0.68, 95% CI 0.53–0.87, p = 0.00163) and CM227 (n = 1,111; HR 0.8, 95% CI 0.67–0.96, p = 0.016), irrespective of treatment type and PD-L1 expression. Among pts with evaluable PD-L1, B⁺ pts treated with nivo+ipi had superior OS versus Ch (n = 617; HR 0.72, 95% CI 0.58–0.90, p = 0.003), while in B⁻ pts there was no significant OS difference between treatment arms (n = 130; HR 1.18, 95% CI 0.79–1.75, p = 0.436), supporting a predictive rather than purely prognostic role for VIGOR-CD8. Conclusions: An AI-derived CD8⁺ immune signature from routine baseline H&E slides was associated with favorable OS in CM227 and predicted differential benefit from nivo+ipi versus Ch. VIGOR-CD8 may help identify advanced NSCLC pts most likely to benefit from first-line dual IO, but further validation in independent and prospective trials is warranted.
Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.
Rotow, Julia K., Baik, Christina S., Dimou, Anastasios, Feng, Jamie, Gordon, Sarah , Chen, Haobin , Desai, Aakash, Niu, Jiaxin, Benyounes, Amin, Sankar, Kamya, Spira, A.I., Stevenson, James, Patel, Shetal , Halmos, Balazs, Shu, Catherine A., Le, Xiuning, Baik, Christina S. , Dimou, Anastasios , Nguyen, Danny , Niu, Jiaxin , Johnson, Melissa L. , Sankar, K. Nathan , Scott, Susan Combs , Stevenson, James, Halmos, Balazs , Shu, Catherine A. , Yu, Helena Alexandra , Le, Xiuning

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8519-8519

10.1200/jco.2026.44.16_suppl.8519 Get It

8519 Background: Non-classical mutations (NCM) of epidermal growth factor receptor (EGFR) represent a broad group of oncogenic mutations in non-small cell lung cancer (NSCLC), often associated with resistance to osimertinib (e.g., P-loop and αC-helix compressing [PACC] mutations). Patients (pts) with NCM have inferior clinical outcomes with a high incidence of CNS metastases (CNSm). Silevertinib (BDTX-1535) is a fourth-generation, covalent EGFR TKI with high CNS penetrance targeting both EGFR classical mutations and NCM. The antitumor activity and safety of silevertinib in pts with advanced NSCLC were evaluated in a Phase 2 trial (NCT05256290). Methods: Pts with advanced EGFR NCM NSCLC who received no prior systemic therapy were enrolled (Cohort 3) based on a local molecular test. Silevertinib 200 mg was administered orally once daily. The primary endpoint of objective response rate (ORR) was assessed using RECIST v1.1. CNS ORR was assessed using Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) in pts with no prior CNS therapy. Secondary endpoints include progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and safety. Results: From February 2024 to July 2025, 43 pts with 35 unique NCMs (including 25 pts with PACC mutations) were enrolled in Cohort 3: median age 70.0 years, 72% female, 74% white, and 42% never smoked cigarettes. As of November 3, 2025, median follow-up was 7.2 months. ORR by RECIST v1.1 is shown in the table. Sixteen pts (37%) had CNSm, including 7 pts (16%) with measurable CNS disease. RANO-BM CNS response was 86% (n=6/7). Complete clearance of EGFR VAF ctDNA was observed in 21/26 (81%) evaluable pts. Serious treatment-related adverse events (TRAEs) were reported in 5 pts (12%), and 4 pts (9%) discontinued treatment due to TRAEs. The most common TRAEs included rash (19%, grade 3), diarrhea (19%, grade 3), stomatitis (9%, grade 3), and paronychia (5%, grade 3). While 77% of pts had a dose reduction, 19/22 (86%) patients with a radiographic response maintained or deepened their response after dose reduction, including all patients with CNS response. Conclusions: Silevertinib demonstrated robust antitumor activity in treatment-naïve pts with a broad spectrum of NCM EGFR driver mutations with high intracranial activity in pts with brain metastases. The safety profile was consistent with the known AEs of the EGFR TKI class. Clinical trial information: NCT05256290 . Data as of November 3, 2025 N ORR n (%) 95% CI DCR n (%) 95% CI ITT Population * 43 26 (60) (44.4, 75.0) 39 (91) (77.9, 97.4) PACC mutations 25 14 (56) (34.9, 75.6) 22 (88) (68.8, 97.5) Compound mutations † 16 11 (69) (41.3, 89.0) 15 (94) (69.8, 99.8) *No pts with classical (E746_A750del or L858R) mutations were enrolled. † Presence of ≥ 2 NCMs. As of December 27, 2025, the 6-month PFS rate was 86% overall and 80% in pts with CNSm; available PFS and DOR data will be presented.